Qiagen N.V. (QGEN) : Traders are bullish on Qiagen N.V. (QGEN) as it has outperformed the S&P 500 by a wide margin of 18.88% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.17%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.14% in the last 1 week, and is up 19.33% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Qiagen NV is up 28.52% in the last 3-month period. Year-to-Date the stock performance stands at -0.43%. The stock has recorded a 20-day Moving Average of 5.85% and the 50-Day Moving Average is 17.63%.
Qiagen N.V. (NASDAQ:QGEN): The stock opened at $27.38 on Friday but the bulls could not build on the opening and the stock topped out at $27.61 for the day. The stock traded down to $27.32 during the day, due to lack of any buying support eventually closed down at $27.53 with a loss of -0.33% for the day. The stock had closed at $27.62 on the previous day. The total traded volume was 408,571 shares.
Also, Equity Analysts at the HSBC upgrades the rating on Qiagen N.V. (NASDAQ:QGEN). The brokerage firm has issued a Buy rating on the shares. The shares were previously rated Hold. The rating by the firm was issued on August 1, 2016.
QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.